Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track BSEM with free AI briefings, catalyst countdowns, and dilution alerts.

BSEM · BioStem Technologies, Inc.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$971,145 Cash on Hand
0.5mo Cash Runway
Follow BSEM by email Get an email when BSEM reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about BSEM, unsubscribe in one click. Privacy

📣 What BSEM Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

💰 Cash Runway & Dilution Risk

BSEM holds $971,145 in cash and short-term investments (as of Sep 30, 2026) and burns about $5.6M/quarter from operations, an estimated runway of 0.5 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 38 · Moderate

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when BSEM files for a raise →

👥 Who Owns BSEM

Insiders 19.9% Other 5%+ holders 21.6% Institutions (20 holders) 16.1% Public and other holders 42.4%
HolderTypeShares% of sharesAs of
Andrew Van Vurst 5%+ holder (13G) 3,854,452 21.59% 2026-09-30
The PNC Financial Services Group, Inc. Institution (13G, 5%+) 1,941,390 10.88% 2026-10-31
Vurst Andrew Smith-van
Chief Operating Officer, Director, 10% o · +2.60M options
Insider 1,789,809 10.03% 2026-10-07
Jason Matuszewski
Chief Executive Officer, Director, 10% o · +3.04M options
Insider 1,553,551 8.70% 2026-10-07
Michael A Fortunato
Chief Accounting Officer · +736,754 options
Insider 69,634 0.39% 2026-11-09
Brandon Poe
Chief Financial Officer · +409,339 options
Insider 60,763 0.34% 2026-11-11
Kenneth Howard Jr Warrington
Director · +21,697 options
Insider 33,928 0.19% 2026-09-15
Jodi Ungrodt
Director
Insider 11,295 0.06% 2026-08-27
Steven D Sonenreich
Director
Insider 7,671 0.04% 2026-08-27
Hannaway Rayna Lesser
Director
Insider 7,671 0.04% 2026-08-27
Mark A Glickman
Director
Insider 7,671 0.04% 2026-08-27
Barry Hassett
Chief Commercial Officer · +215,423 options
Insider 5,256 0.03% 2026-11-01

Share count 17,849,471 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full BSEM picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for BSEM and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.